Design and Expression of Fasciola hepatica Multiepitope Constructs Using mRNA Vaccine Technology
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26031190 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Javier Sánchez-Montejo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca Research Centre for Tropical Diseases at the Un…. Hauptthemen laut MEDLINE: Fasciola hepatica, Epitopes, RNA, Messenger, Fascioliasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Ministerio de Ciencia e Innovación, European Union.
Abstract (Originalsprache)
Fasciola hepatica is a parasitic trematode responsible for fascioliasis, a significant zoonotic disease affecting livestock worldwide, as well as humans. This study identifies peptides with potential for use in vaccines against Fasciola hepatica and validates multi-epitope constructs from those peptides in vitro. Putative protein sequences derived from the genome of F. hepatica were integrated with phase-specific transcriptomic data to prioritize highly expressed proteins. Among these, extracellular proteins were selected using DeepLoc 2.0 and strong binding affinities across diverse human and murine alleles were predicted with the IEDB MHC II tool. Peptides were further selected based on their toxicity, immunogenicity, and allergenicity. Finally, 55 high-priority candidates were obtained. To express these candidates, mRNA constructs encoding various combinations of these peptides were designed, synthesized using in vitro transcription with T7 or SP6 RNA polymerases, and transfected into cells for expression analysis. SP6 polymerase produced proper capping using CleanCapAG and was far superior in transcribing peptide constructs. Peptides fused in frame with eGFP were expressed efficiently, particularly when peptides were positioned at the 3′ terminus, opening a new field of peptide vaccines created using mRNA technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), 37007 Salamanca, Spain.
- Infectious Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.
- Department of Microbiology, Immunology and Cancer Biology, Center for RNA Science and Medicine, University of Virginia, Charlottesville, VA 22903, USA.
ORCID-Profile: Javier Sánchez-Montejo, Raúl Manzano-Román, Julio López-Abán, Mariano A García-Blanco, Antonio Muro
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Ministerio de Ciencia e Innovación
- European Union
- University of Virginia
- Junta de Castilla y León
Zitieren
APA
Sánchez-Montejo, J., Strilets, T., Manzano-Román, R., López-Abán, J., García-Blanco, M. A., Vicente, B., & Muro, A. (2025). Design and Expression of Fasciola hepatica Multiepitope Constructs Using mRNA Vaccine Technology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031190
Vancouver
Sánchez-Montejo J, Strilets T, Manzano-Román R, López-Abán J, García-Blanco MA, Vicente B, et al. Design and Expression of Fasciola hepatica Multiepitope Constructs Using mRNA Vaccine Technology. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031190
BibTeX
@article{SnchezMontejo2025,
author = {Sánchez-Montejo, Javier and Strilets, Tania and Manzano-Román, Raúl and López-Abán, Julio and García-Blanco, Mariano A and Vicente, Belén and Muro, Antonio},
title = {Design and Expression of Fasciola hepatica Multiepitope Constructs Using mRNA Vaccine Technology},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26031190}
}
EUVIMED